| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff10481d6146513649f19b680dcb293f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_237f32a5abb8d4194a89feb2e61b30dd |
| publicationDate |
2021-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021060070-A1 |
| titleOfInvention |
Adoptive cell therapy and methods of dosing thereof |
| abstract |
The present disclosure provides methods for the administration of engineered cells, such as T cells, to subjects for adoptive cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells express chimeric antigen receptors (CARs) and/or T cell receptors (TCRs), and optionally, other molecules to overcome the immunosuppressive tumor microenvironment. Methods provided herein may employ a fractionated dosing regimen which may further comprise monitoring the development of a toxicity and managing the symptoms thereof. |
| priorityDate |
2019-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |